Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer - Wikidata - awgldk - TriplyDB

Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer

Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer

http://www.wikidata.org/entity/Q33614221

about

Chronic inflammation and cytokines in the tumor microenvironment.The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC Cellular and molecular immunology of lung cancer: therapeutic implications.Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells.Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro.Role of tumor-associated macrophages in human malignancies: friend or foe?Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.Oxaliplatin and infliximab synergize to induce regression of colon cancer.

P2860

Q33678275-3CE75F27-DFB5-45FA-8875-469AEBC3D5E6 Q33974870-1696BC52-C6C4-449A-BA06-089296FA6AE0 Q36130505-59FD4798-C4E2-4984-9EE0-4276546D668B Q36383090-EB3A57D1-835F-44BE-8EB3-61783B0F0008 Q37475819-422B1C4A-B45E-4FF7-8FDB-9BF4800A529D Q37641733-E6A62A0F-BC13-44A1-8523-B8CD683882AE Q38883475-DAA022F2-774F-4AF4-AAB8-63DCDBA6D0F9 Q38904869-34D20BCD-15AE-4020-B653-0E327A58B2B8 Q41745482-953A7B89-7E7C-4551-9E8A-FA2577C725EC Q49693459-1AA949C2-F944-44E5-AC05-7DC27784ADC0

P2860

Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer

http://www.wikidata.org/entity/Q33614221

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@ast

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@en

type

label

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@ast

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@en

prefLabel

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@ast

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@en

P1433

Q33614221-5FF3B1DB-BD6B-40A5-90B0-8124969C40AE

P1476

Q33614221-9F9C13A1-782E-4561-B6D3-8DEFCF6CC66C

P2093

Q33614221-0CA1B48E-F8A9-4752-A5AF-4DB1B007C3EB

Q33614221-27ED1844-6536-467D-ABC7-4C2806B4E293

Q33614221-6FFDB163-F2CC-4F2F-A005-6C1CF44F241F

Q33614221-DB170489-A64C-4CF4-BEA5-3403F01668B9

Q33614221-FF9A88C7-3BE6-404D-B04E-17A0244CB695

P2860

Q33614221-0DEFD18C-2575-471A-825A-1AF4BB689D1A

Q33614221-1B8FF94F-80C6-4F8F-B3E0-1CEB7F92263F

Q33614221-2169FBF5-DB54-4E2E-B2E5-8FD365CA8841

Q33614221-24F2F809-8FA8-42EE-AD08-CE1FF8F3936E

Q33614221-2ECDDFA9-176A-4DF0-B502-4C92F13A7AB6

Q33614221-3225C891-F83B-4C32-AE56-BFF7384298FE

Q33614221-3D3A4694-6757-45F3-A2AD-FC24BED691D7

Q33614221-416E4908-0FAA-46B8-B5C4-D866B7D79A3C

Q33614221-4DE83213-B317-4B06-A578-6BD17206E0B9

Q33614221-5C86AB39-5BAA-4294-84FE-56920B468E9A

P2888

Q33614221-F3F90FDB-2E11-466E-8843-A77AAF1E9B0D

P304

Q33614221-7FB61AFD-9C3D-4E89-9E23-A94EBFED575F

P31

Q33614221-4A3014D1-68E8-41F3-9C75-AB0819272575

P356

Q33614221-129E0AA4-0161-4400-8413-E2B032914DD0

P407

Q33614221-B51FD1AB-D0F5-4EEC-834A-10E0C93BA84A

P478

Q33614221-16DA4060-298B-454F-A0A5-5515EA69B228

P577

Q33614221-0424BD22-35F1-44AF-A868-FC3AD7E8F557

P5875

Q33614221-34D57CCB-20DA-4213-985A-1D27E5553F46

P6179

Q33614221-A57E87CD-F8A2-401D-AC14-D05B6954CCEF

P698

Q33614221-D9E28743-B2A2-4DEC-BD70-6AB3B2092FB5

P921

Q33614221-d6a887e2-bad5-4015-b908-79d220d3c39c

P932

Q33614221-6719B9D7-966D-4EFA-B844-1E20815406AD

P356

1471-2407-10-323

P1433

P1476

Tumour necrosis factor-alpha e ...... in non-small cell lung cancer

@en

P2093

Aarti Shikotra

http://www.w3.org/2001/XMLSchema#string

Chandra M Ohri

http://www.w3.org/2001/XMLSchema#string

David A Waller

http://www.w3.org/2001/XMLSchema#string

Peter Bradding

http://www.w3.org/2001/XMLSchema#string

Ruth H Green

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic immune activation and inflammation as the cause of malignancy

TNF-R1 signaling: a beautiful pathway

The TNF and TNF receptor superfamilies: integrating mammalian biology

Revisions in the International System for Staging Lung Cancer

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

P2888

1471-2407-10-323

P304

323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-323

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44697539

http://www.w3.org/2001/XMLSchema#string

P6179

1014047259

http://www.w3.org/2001/XMLSchema#string

P698

20573209

http://www.w3.org/2001/XMLSchema#string

P921

P932

2909205

http://www.w3.org/2001/XMLSchema#string